Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer

Lung cancer still represents the leading cause of cancer-related mortality. However, the recent advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically improved prognosis of advanced non-small cell lung cancer (NSCLC) patients. Anaplastic lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavalà, Tiziana, Mariniello, Annapaola, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798861/
https://www.ncbi.nlm.nih.gov/pubmed/35117063
http://dx.doi.org/10.21037/tcr.2018.10.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798861/
https://www.ncbi.nlm.nih.gov/pubmed/35117063
http://dx.doi.org/10.21037/tcr.2018.10.23

Ejemplares similares